Follow up at 1 and 2 years of corrected age for participants in the AZTEC study (Azithromycin Therapy for Chronic Lung Disease of Prematurity)
Phase 3
- Conditions
- PrematurityPregnancy and Childbirth
- Registration Number
- ISRCTN47442783
- Lead Sponsor
- Cardiff University
- Brief Summary
2022 Protocol article in https://pubmed.ncbi.nlm.nih.gov/36131325/ (added 22/09/2022)
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Ongoing
- Sex
- All
- Target Recruitment
- 500
Inclusion Criteria
1. Participation in the AZTEC trial
2. Survival at 36 weeks PCA
3. Consent provided by the parents/guardians to be contacted for follow-up at one and two years of corrected age
Exclusion Criteria
1. Withdrawal from AZTEC
2. Parents/guardians did not provide consent to follow up at one and two years corrected age
3. Death prior to 36 weeks’ PCA
4. Survival not confirmed
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method